Literature DB >> 21177895

Rifampin stability in 7H9 broth and Löwenstein-Jensen medium.

Xia Yu1, Guanglu Jiang, Huiwen Li, Yanlin Zhao, Hongtao Zhang, Liping Zhao, Yu Ma, Christopher Coulter, Hairong Huang.   

Abstract

The objectives of this study were to monitor the stability of rifampin (RIF) in Löwenstein-Jensen medium (L-J medium) and 7H9 broth, which are the media commonly used for drug susceptibility testing (DST) of Mycobacterium tuberculosis. Rifampin degradation in stock solution, 7H9 broth, and L-J medium and during the inspissation process for L-J medium preparation was serially monitored by high-performance liquid chromatography (HPLC). L-J medium-based DST was conducted to examine the effect of L-J medium storage on the DST outcome. The RIF stock solution was stable for at least 3 months when kept at either 4°C or -20°C; RIF in 7H9 broth and L-J medium was almost 50% decayed after 1 week of storage at 37°C, and rifampin could not be detected in 7H9 or L-J medium after 3 weeks or 6 weeks of storage at 37°C. Approximately half of the drug was decomposed after 4 months of storage at 4°C for both media, and after 6 months of storage at 4°C, RIF in L-J medium was undetectable, while 38% of RIF remained in 7H9 medium. Approximately 21, 24, 29, and 35% RIF degradations were detected when the L-J medium was coagulated at 75°C, 80°C, 85°C, and 90°C, respectively. The DST outcomes when using L-J medium stored for different periods of time were consistent with the RIF concentration monitoring data. Rifampin in stock solution is stable for at least 3 months at a reduced storage temperature. Media containing RIF should be prepared strictly according to validated standard operating procedures. RIF degradation is a possible reason for false resistance categorizations of M. tuberculosis isolates in the clinical laboratory.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21177895      PMCID: PMC3067696          DOI: 10.1128/JCM.01951-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

Review 1.  Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.

Authors:  S Ramaswamy; J M Musser
Journal:  Tuber Lung Dis       Date:  1998

2.  Sustained release characteristics of rifampin-loaded microsphere formulations in nonhuman primates.

Authors:  Debra Quenelle; Gary A Winchester; Jay K Staas; Darrel E Hoskins; Esther W Barrow; William W Barrow
Journal:  Drug Deliv       Date:  2004 Jul-Aug       Impact factor: 6.419

3.  Stability of antimycobacterial drugs in susceptibility testing.

Authors:  M E Griffith; H L Bodily
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 4.  Multidrug-resistant and extensively drug-resistant tuberculosis: a review.

Authors:  Edward D Chan; Michael D Iseman
Journal:  Curr Opin Infect Dis       Date:  2008-12       Impact factor: 4.915

5.  Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay.

Authors:  S G Franzblau; R S Witzig; J C McLaughlin; P Torres; G Madico; A Hernandez; M T Degnan; M B Cook; V K Quenzer; R M Ferguson; R H Gilman
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

6.  Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.

Authors:  M A Espinal; S J Kim; P G Suarez; K M Kam; A G Khomenko; G B Migliori; J Baéz; A Kochi; C Dye; M C Raviglione
Journal:  JAMA       Date:  2000-05-17       Impact factor: 56.272

7.  [The comparative results of the antibiograms for Mycobacterium tuberculosis performed in 2 different laboratories].

Authors:  D Homorodean; C Diaconescu; S E Henegariu; S D Creţu; C D Zamora
Journal:  Pneumoftiziologia       Date:  1997 Jan-Mar

8.  Transition times to oral feeding in premature infants with and without apnea.

Authors:  M B Mandich; S K Ritchie; M Mullett
Journal:  J Obstet Gynecol Neonatal Nurs       Date:  1996 Nov-Dec

9.  Determination of ethambutol in plasma by high-performance liquid chromatography after pre-column derivatization.

Authors:  P Chenevier; L Massias; D Gueylard; R Farinotti
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-04-24

10.  Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.

Authors:  G B Migliori; M Espinal; I D Danilova; V V Punga; M Grzemska; M C Raviglione
Journal:  Int J Tuberc Lung Dis       Date:  2002-10       Impact factor: 2.373

View more
  8 in total

1.  Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs In Vitro.

Authors:  E D Pieterman; M J Sarink; C Sala; S T Cole; J E M de Steenwinkel; H I Bax
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

2.  Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.

Authors:  Kohta Saito; Thulasi Warrier; Selin Somersan-Karakaya; Lina Kaminski; Jianjie Mi; Xiuju Jiang; Suna Park; Kristi Shigyo; Ben Gold; Julia Roberts; Elaina Weber; William R Jacobs; Carl F Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-30       Impact factor: 11.205

3.  Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.

Authors:  Xia Yu; Guirong Wang; Suting Chen; Guomei Wei; Yuanyuan Shang; Lingling Dong; Thomas Schön; Danesh Moradigaravand; Julian Parkhill; Sharon J Peacock; Claudio U Köser; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

4.  Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates.

Authors:  Wei Jing; Yu Pang; Zhaojing Zong; Jing Wang; Ru Guo; Fengmin Huo; Guanglu Jiang; Yifeng Ma; Hairong Huang; Naihui Chu
Journal:  Front Microbiol       Date:  2017-09-14       Impact factor: 5.640

5.  Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using Mycobacterium smegmatis as a tuberculosis model.

Authors:  Jorge Ragusa; Daniela Gonzalez; Sumin Li; Sandra Noriega; Maciej Skotak; Gustavo Larsen
Journal:  Heliyon       Date:  2019-04-28

6.  Screening of the antimycobacterial activity of novel lipophilic agents by the modified broth based method.

Authors:  Mehdi Zandhaghighi; Kiarash Ghazvini; Zahra Meshkat; Seyed Abdolrahim Rezaee; Mohammad Derakhshan; Saman Soleimanpour; Farzin Hadizadeh
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2016-02-11

7.  A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.

Authors:  Oskar Clewe; Linda Aulin; Yanmin Hu; Anthony R M Coates; Ulrika S H Simonsson
Journal:  J Antimicrob Chemother       Date:  2015-12-24       Impact factor: 5.790

8.  Repurposing clinically approved cephalosporins for tuberculosis therapy.

Authors:  Santiago Ramón-García; Rubén González Del Río; Angel Santos Villarejo; Gaye D Sweet; Fraser Cunningham; David Barros; Lluís Ballell; Alfonso Mendoza-Losana; Santiago Ferrer-Bazaga; Charles J Thompson
Journal:  Sci Rep       Date:  2016-09-28       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.